

# ISBT128 Labeling for Cellular Therapy Products: An International Survey




Advancing Transfusion and Cellular Therapies Worldwide




# Country and Number of Participants Responding to Survey (n=318)

Australia	3	India	1	Singapore	2
Austria	1	Israel	1	Sweden	2
Canada	16	Japan	1	Taiwan	3
China	2	Malaysia	2	Thailand	1
Czech Republic	1	Mexico	1	Turkey	1
Denmark	3	Netherlands	2	United Arab Emirates	1
Finland	2	New Zealand	1	United Kingdom	4
France	2	Peru	1	United States of America	241
Germany	2	Poland	1	Uruguay	1
Ghana	1	Portugal	2	Uzbekistan	1
Greece	3	Puerto Rico	1	Vietnam	3
Hong Kong	4	Saudi Arabia	3		


**Q2: If your facility is a collection facility, how many cellular therapy donations do you collect per year? (n=282)**




**Q3: If your facility is a processing laboratory, how many cellular therapy donations do you process per year? (n=292)**




**Q4: If your facility is a cord blood bank, how many products do you bank per year? (n=80)**




## Q5: Who is your facility accredited by? (n=293)




**Q6: Are you part of the same business entity as a facility that has implemented ISBT 128 for blood (n=285)**




**Q7: Are you part of the same business entity as a facility that has implemented ISBT 128 for tissues (n=273)**




**Q8: Have you implemented ISBT 128 terminology on your cellular therapy product labels? (n=286)**




**Q9: Have you implemented the ISBT 128 label design on your cellular therapy product labels? (n=281)**



**Q10: Have you implemented the ISBT 128 bar codes on your cellular therapy product labels? (n=280)**




# Q11: If you have not implemented ISBT128 label design or bar codes, why not? (Select all that apply) (n=178)




**Q11 'Other' responses specified by respondents to: if you have not implemented ISBT128 label design or bar codes, why not? (n=56)**

	n
In the process of planning, implementing or validating	25
No time/staff resources for validation/completion	8
Low product number/autologous products	3
Customers/suppliers have not implemented ISBT128	4
Vendors are not ready/awaiting software upgrades	3
Currently budgeting for system	2
NMDP provides labels and they are not ISBT128	2
Other priorities	2
Use Eurocode alternative to ISBT128 barcode labeling	1
German language required	1
Not all of our investigational TC products are covered by ISBT128 labeling	1
Need to implement across multiple IT systems which requires time	1
No response from site whenever we ask for information	1
Had to change vendors responsible for project due to delays in implementation	1
We are transporter of cellular materials (no processor/therapy activity) and see need to have transport labels consistent with ISBT128	1


**Q12: When do you plan to implement ISBT 128 label design?  
(n=199)**




**Q13: When do you plan to implement ISBT 128 bar codes?  
(n=204)**




**Q14: If you have implemented ISBT 128 for cellular therapy products are you? (Select all that apply) (n=94)**




**Q15: If you contacted ICCBBA for support, did they meet your expectations in terms of both the quality and timeliness of their response (n=258)**



**Q16: Did the request process for new codes work efficiently?  
(n=240)**



**Q17: Did you find the documentation from ICCBBA to be sufficient for your needs? (n=239)**



**The volume of information is difficult/confusing**

- Terminology/codes should be better defined
- Need to provide more examples
- Label formats should be more clear (Sample labels may/may not be 'scannable')